Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | APP | P05067 | 4/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28800357 | 1.00 | ATM (0.68) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL20255734 | 0.89 | ATM (0.57) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL14032636 | 0.89 | ATM (0.65) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL14074458 | 0.89 | ATM (0.65) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL3173567 | 0.89 | ATM (0.58) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL15159951 | 0.87 | ATM (0.73) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL7449539 | 0.87 | CTSS (0.55) | ATMAPPCTSSCTSKCTSL | |
| SCHEMBL13285960 | 0.87 | CTRB1 (0.52) | ATMCTSLCYP3A4 | |
| SCHEMBL10283715 | 0.87 | CTRB1 (0.52) | ATMCTSLCYP3A4 | |
| SCHEMBL89573 | 0.86 | ATM (0.65) | ATMAPPCTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638446-A1 | THIADIAZOLE DERIVATIVES AS INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240270740-A1 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. | 2024-08-15 | — | — | US | disclosed |
| WO-2024137607-A1 | THIADIAZOLE DERIVATIVES AS INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-11220482-B2 | Aminopyridinemethanol compounds and their use | UNIVERSITE AMIENS PICARDIE JULES VERNE (FR) | 2022-01-11 | — | — | US | disclosed |
| CN-113906027-A | Phenethyl substituted imidazo [4,5-c ] quinoline compounds with N-1 branched groups | 3M创新有限公司 | 2022-01-07 | — | — | CN | disclosed |
| US-20200255379-A1 | NOVEL AMINOPYRIDINEMETHANOL COMPOUNDS AND THEIR USE | UNIV AMIENS PICARDIE JULES VERNE (FR) | 2020-08-13 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| CN-1233237-A | Heteroaryl succinamides and their use as metalloproteinase inhibitors | AGOURON PHARMA (US) | 1999-10-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | ATM 4617/4885APP 4570/4885CTSS 1068/4885 |
| US-11220482-B2 | Aminopyridinemethanol compounds and their use | QDPR, PNMT, CYP3A43 | ATM 3863/4885APP 439/4885CTSS 3161/4885 |
| US-20240270740-A1 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | CGAS, GMPS, PRKG1 | ATM 122/4885APP 2523/4885CTSS 1220/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | ATM 4617/4885APP 4570/4885CTSS 1068/4885 |
| US-20200255379-A1 | NOVEL AMINOPYRIDINEMETHANOL COMPOUNDS AND THEIR USE | QDPR, PNMT, CYP3A43 | ATM 4012/4885APP 538/4885CTSS 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.